T G Hullinger
Overview
Explore the profile of T G Hullinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
100
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Crean S, Meneski J, Hullinger T, Reilly M, DeBoever E, Taichman R
Br J Haematol
. 2004 Feb;
124(4):534-46.
PMID: 14984505
Haematopoietic progenitor cells proliferate and develop predominantly when they adhere to bone marrow stromal cells such as osteoblasts. Therefore, changes in adhesion may be a common mechanism by which stem...
2.
Hullinger T, Panek R, Xu X, Karathanasis S
J Biol Chem
. 2001 Oct;
276(50):46807-14.
PMID: 11585816
Scavenger receptor class B, type I (SR-BI), is a high density lipoprotein receptor that mediates the flux of cholesterol between high density lipoprotein and cells. Recent evidence suggests that SR-BI...
3.
Hullinger T, Pan Q, Viswanathan H, Somerman M
Exp Cell Res
. 2000 Dec;
262(1):69-74.
PMID: 11120606
Members of the transforming growth factor superfamily are known to transduce signals via the activation of Smad proteins. Ligand binding to transmembrane cell surface receptors triggers the phosphorylation of pathway-specific...
4.
Bunyaratavej P, Hullinger T, Somerman M
Exp Cell Res
. 2000 Oct;
260(2):324-33.
PMID: 11035927
It is well established that bone metastases comprise bone; however, the exact factors/mechanisms involved remain unknown. We hypothesized that tumor cells secreted factors capable of altering normal bone metabolism. The...
5.
Hullinger T, Taichman R, Linseman D, Somerman M
J Cell Biochem
. 2000 Jun;
78(4):607-16.
PMID: 10861858
Tumor cells frequently have pronounced effects on the skeleton including bone destruction, bone pain, hypercalcemia, and depletion of bone marrow cells. Despite the serious sequelae associated with skeletal metastasis, the...
6.
Hullinger T, McCauley L, DeJoode M, Somerman M
Prostate
. 1998 Jul;
36(1):14-22.
PMID: 9650911
Background: Despite the high incidence and serious consequences of skeletal metastasis in prostate cancer patients, the mechanisms involved in establishing secondary lesions in bone are not well-understood. In this study,...
7.
Mills C, Northrup J, Hullinger T, Simmons C, Shebuski R, Jones D
Cardiovasc Res
. 1996 Nov;
32(5):954-61.
PMID: 8944827
Objective: Restenosis is a common problem which limits the effectiveness of percutaneous transluminal coronary angioplasty (PTCA). The cellular mechanisms of restenosis appear to involve smooth muscle cell (SMC) migration to...
8.
Hartman J, Kurc G, Hullinger T, Wall T, Sheehy R, Shebuski R
J Pharmacol Exp Ther
. 1994 Sep;
270(3):1071-6.
PMID: 7523655
The objective of this investigation was to determine the role of nitric oxide synthase in the action of the angiotensin-converting enzyme inhibitor, ramiprilat, to reduce myocardial ischemia/reperfusion injury. Ramiprilat, the...
9.
Hartman J, Olszanski D, Hullinger T, Brunden M
J Pharmacol Toxicol Methods
. 1994 Jun;
31(3):153-60.
PMID: 8068977
The objective of this investigation was to validate a transit-time ultrasound blood flow metering system in vivo. Implanted chronically and acutely on the ascending aorta of the dog, the transit-time...
10.
Hartman J, Wall T, Hullinger T, Shebuski R
J Cardiovasc Pharmacol
. 1993 Jun;
21(6):996-1003.
PMID: 7687728
We wished to determine, using a novel specific antagonist of BK2, HOE 140, (a) if the angiotensin-converting enzyme (ACE) inhibitor, ramiprilat, reduces myocardial infarct size in a well-established animal model...